Rheumatoid Arthritis and Myositis Cohort
Study Details
Study Description
Brief Summary
The primary objective of this research is to establish a well characterized clinical and longitudinal cohort for individuals with Rheumatoid Arthritis (RA) and Myositis to create a place to maintain blood, urine, stool specimens, excess tissue from procedures, and clinical data, which may be accessed for future research purposes.
Specific research objectives of this cohort include:
-
Observe the response that immunosuppressive medications have on the immune cell population and cytokines in individuals with RA or Myositis.
-
Observe the role that the intestinal microbiome has on the immune cell population and cytokines in individuals with RA or Myositis.
-
Observe the connection between intestinal inflammation has on the immune cell population and cytokines in individuals with RA or Myositis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Autoimmune diseases are together the third most common type of disease that affect individuals in the United States. In 2005 the National Institute of Health estimated that 23.5 million people have an autoimmune condition. Previously considered to be rare, epidemiological studies have shown that there are nearly 100 different autoimmune diseases. Examples include organ specific autoimmune disease such as Primary Biliary Cirrhosis (PBC), or Systematic Lupus Erythematosus, which reflects immunological dysfunction involving multiple organs. As the prevalence and incidence of autoimmune diseases continue to rise, it creates a burden on individuals, their families, and society. The burden is noticeable through medical costs, diminished quality of life, and loss of productivity. The burden of this disease demands a comprehensive treatment that includes overall wellness.
The human gastrointestinal tract is home to trillions of microorganisms including bacteria, viruses, fungi, and protozoa, which together are referred to as the gut microbiome. Research in recent years has underlined that the microorganisms can influence varying physiological aspects such as the immune system, metabolism, and behavior. The microbiome has further been implicated in the pathogenesis of autoimmune diseases. In Systematic Lupus Erythematosus for example, modifications in the intestinal flora have been documented while changes in gut commensal and periodontal diseases have been brought forth as factors for consideration in the development of Rheumatoid Arthritis. Similarly, autoimmune diseases such as Systematic Sclerosis, Sjogren's Syndrome, and Anti-phospholipid Syndrome have been noted to share alterations in the gut microbiome.
Emerging research on the gut microbiome has demonstrated that diet plays a critical role in the make-up of gut microbiome and several experiments have shown that dietary modifications can prompt significant changes in the gut microbial composition. However, little is presently understood about the precise mechanisms and unique interactions between the gut microbiome, diet, and the pathogenesis of autoimmune diseases.
To investigate the triangular link between a patient's diet, their microbiome, and their disease activity, the investigators are seeking to establish a registry to track patients with autoimmune disease diagnoses. Furthermore, the investigators are looking to track the changes in the microbiome, diet, and disease progression as patients are introduced and sustained on medication.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients with Rheumatoid Arthritis and/or Myositis All patients 18 years or older who have been diagnosed with Rheumatoid Arthritis according to the 2010 ACR/EULAR Classification Criteria. All patients 18 years or older who have been diagnosed with Myositis according to the 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies Classification Criteria. |
Outcome Measures
Primary Outcome Measures
- Change in IL-1, IL-6, CXCL10 and Immune Cell Population due to Immunosuppressive Medication [1 year]
Observe the response that immunosuppressive medications have on the immune cell population and cytokines in individuals with RA or Myositis.
- Change in IL-1, IL-6, CXCL10 and Immune Cell Population in response to Intestinal Microbiome [1 year]
Observe the role that the intestinal microbiome has on the immune cell population and cytokines in individuals with RA or Myositis.
- Change in IL-1, IL-6, CXCL10 and Immune Cell Population in response to Intestinal Inflammation [1 year]
Observe the connection between intestinal inflammation has on the immune cell population and cytokines in individuals with RA or Myositis.
Secondary Outcome Measures
- Change in IL-1, IL-6, CXCL10 and Immune Cell Population due to Immunosuppressive Medication [10 years]
Observe the response that immunosuppressive medications have on the immune cell population and cytokines in individuals with RA or Myositis.
- Change in IL-1, IL-6, CXCL10 and Immune Cell Population due to changes in the intestinal microbiome [10 years]
Observe the response that immunosuppressive medications have on the immune cell population and cytokines in individuals with RA or Myositis.
- Change in IL-1, IL-6, CXCL10 and Immune Cell Population due to Intestinal Inflammation [10 years]
Observe the connection between intestinal inflammation has on the immune cell population and cytokines in individuals with RA or Myositis.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects must be 18 years or older
-
Diagnosed RA by a rheumatologist determined by the 2010 ACR/EULAR Classification Criteria.
-
Diagnosed Myositis by a rheumatologist determined by the 2017 American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies
-
Able to read and write in English or Spanish
Exclusion Criteria:
- Subject is less than 18 years old
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Attune Health Research, Inc.
- ONCOtracker Inc
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'Dell JR, Kazi S. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012 May;64(5):640-7. doi: 10.1002/acr.21649.
- Bethesda. National Institutes of Health Autoimmune Disease Coordinating Committee Report. The Institutes, 2002.
- De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019 Jan;195(1):74-85. doi: 10.1111/cei.13158.
- Services USDoHaH. Progress in Autoimmune Diseases and Research. National Institutes of Health: The autoimmune Diseases Coordinating Committee, 2005:1-126.
- Singh RK, Chang HW, Yan D, Lee KM, Ucmak D, Wong K, Abrouk M, Farahnik B, Nakamura M, Zhu TH, Bhutani T, Liao W. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017 Apr 8;15(1):73. doi: 10.1186/s12967-017-1175-y.
- Vieira SM, Pagovich OE, Kriegel MA. Diet, microbiota and autoimmune diseases. Lupus. 2014 May;23(6):518-26. doi: 10.1177/0961203313501401.
- Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015 Oct;278(4):369-95. doi: 10.1111/joim.12395. Epub 2015 Jul 25.
- Xu J, Yang Y. Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases. Gut Microbes. 2021 Jan-Dec;13(1):1936379. doi: 10.1080/19490976.2021.1936379.
- RAMC2022